Table 1

Clinical and laboratory findings for 42 patients with ankylosing spondylitis treated with infliximab
Finding
 BASDAI
 BASMI
 BASFI
 PatGA
 PhysGA
 NRS-P
 ESR (mm/h)
 CRP (mg/l)
At time point 1a
Mean ± SD
 2.5 ± 1.8**
 2.7 ± 2.0*
 2.9 ± 2.4**
 2.6 ± 1.5**
 2.6 ± 2.1**
 2.6 ± 2.1**
 10.5 ± 7.3**
 3.1 ± 4.2**
Median
 2.4
 2.0
 2.5
 4.0
 2.0
 2.0
 8.0
 1.1
Range
 0.0 - 6.8
 0.0 - 7.0
 0.0 - 8.3
 0.0 - 8.0
 0.0 - 4.0
 0.0 - 7.0
 2.0 - 32.0
 0.0 - 19.0
At time point 2a
Mean ± SD
 6.1 ± 1.4**
 3.2 ± 2.2*
 5.8 ± 1.8**
 6.9 ± 2.1**
 7.0 ± 1.5**
 7.1 ± 1.7**
 31.5 ± 29.7**
 20.7 ± 23.7**
Median
 6.2
 3.0
 5.7
 7.0
 7.0
 7.0
 23.0
 14.0
Range
 4.0 - 9.2
 0.0 - 9.0
 1.2 - 9.1
 4.0 - 10.0
 4.0 - 10.0
 0.0 - 10.0
 4.0 - 150.0
 0.3 - 126.0
Change between time points 1 and 2
Mean ± SD
 3.6 ± 1.7
 0.5 ± 1.5
 2.9 ± 2.0
 4.3 ± 1.9
 4.4 ± 1.8
 4.5 ± 2.2
 21.0 ± 29.7
 17.6 ± 23.4
Median
 3.6
 0.5
 2.5
 4.0
 4.0
 4.0
 12.0
 11.5
Range
 -1.2 - 6.7
 -4.0 - 3.0
 -0.5 - 7.8
 -2.0 - 8.0
 -2.0 - 8.0
 -1.0 - 8.0
 -6.0 - 146.0
 -6.3 - 123.0

aTime point 1 is the time point at which infliximab treatment was discontinued; time point 2 is that when retreatment began. *P < 0.05, **P < 0.001, when means at time points 1 and 2 are compared. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Function Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; NRS-P, numerical rating scale for pain; PatGA, patient's global assessment; PhysGA, physician's global assessment; SD, standard deviation.

Baraliakos et al. Arthritis Research & Therapy 2005 7:R439   doi:10.1186/ar1693